Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04849650 · ClinicalTrials.gov registry record · Phase 1

PK Study of IV and Oral Amisulpride in Subjects With Severe Renal Impairment

A Phase 1 study, sponsored by Acacia Pharma.

Completed
Registry status
Phase 1
Development phase
12
Enrollment target

NCT04849650 is a Phase 1 study that has completed, run by Acacia Pharma. The registered enrollment target is 12 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04849650, a Phase 1 study, has completed, sponsored by Acacia Pharma.

COMPLETED
Registry status
Phase 1
Development phase
12 participants
Enrollment target

Study Summary

The aim of the study is to understand how Amisulpride is taken up and distributed around the body and how quickly it is eliminated, when given by mouth and into a vein in adults with severe kidney disease. In addition it is important to understand how well tolerated Amisulpride is in this patient population. Healthy adults will be studied to provide a comparison.

Interventions

  • DRUG Amisulpride IV
  • DRUG Amisulpride Oral Tablet

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2021-06-03
Est. Completion 2021-10-30
Phase Phase 1

Sponsor

Acacia Pharma

9 total trials

What the Registry Record Tells You About NCT04849650

The ClinicalTrials.gov registry entry for NCT04849650 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Acacia Pharma, which has 9 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Amisulpride IV is the first listed.

NCT04849650 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04849650 about?

NCT04849650 is a clinical study titled "PK Study of IV and Oral Amisulpride in Subjects With Severe Renal Impairment". The aim of the study is to understand how Amisulpride is taken up and distributed around the body and how quickly it is eliminated, when given by mouth and into a vein in adults with severe kidney disease. In addition it is important to understand how well tolerated Amisulpride is in this patient po...

What is the current status of trial NCT04849650?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2021-06-03. Estimated completion is 2021-10-30.

What interventions are being tested in trial NCT04849650?

The interventions under investigation include: Amisulpride IV (DRUG), Amisulpride Oral Tablet (DRUG).

Who is sponsoring clinical trial NCT04849650?

This trial is sponsored by Acacia Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.